| Literature DB >> 31719975 |
Reza Ranjbar1, Abbas Farahani2.
Abstract
Background: Antimicrobial resistance in multidrug-resistant Acinetobacter baumannii (MDR-AB) isolated from burn wound infections is a major concern in intensive care or burns units worldwide, and molecular studies are considered critical strategies for control of MDR-AB outbreaks in this regard. Thus, in this study, antibiotic resistance, biofilm-forming ability, molecular epidemiology of MDR A. baumannii strains recovered from patients with burns were investigated in three major hospital centers of Iran.Entities:
Keywords: Antimicrobial resistance; Biofilm; Clone dissemination; Integron; OXA carbapenemase
Mesh:
Substances:
Year: 2019 PMID: 31719975 PMCID: PMC6836547 DOI: 10.1186/s13756-019-0612-5
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Primers sequences used in this study
| Primers | Forward sequence | Reverse Sequence | Annealing Temperature (°C) | Expected size (pb) | Reference |
|---|---|---|---|---|---|
| OXA-51 | TAATGCTTTGATCGGCCTTG | TGGATTGCACTTCATCTTGG | 52 | 353 | [ |
| OXA-23 | GATCGGATTGGAGAACCAGA | ATTTCTGACCGCATTTCCAT | 52 | 501 | |
| OXA-40 | GGTTAGTTGGCCCCCTTAAA | AGTTGAGCGAAAAGGGGATT | 52 | 246 | |
| OXA-58 | AAGTATTGGGGCTTGTGCTG | CCCCTCTGCGCTCTACATAC | 52 | 599 | |
| OXA-143 | TGGCACTTTCAGCAGTTCCT | TAATCTTGAGGGGGCCAACC | 52 | 149 | |
| IS | CACGAATGCAGAAGTTG | CGACGAATACTATGACAC | 50 | 548 | |
| IS | GTGTCATAGTATTCGTCG | ATTTCTGACCGCATTTCCAT | 50 | 875 | |
| IS | CAAGGCCGATCAAAGCATTA | GTGTCATAGTATTCGTCG | 50 | 359 | |
| OXA-253 | TTGTTGCCTTTACTTAGTTGC | CAAAATTTTAAGACGGATCG | 56 | 768 | [ |
| GES | ATGCGCTTCATTCACGCAC | CTATTTGTCCGTGCTCAGG | 55 | 860 | [ |
| PER-1 | ATGAATGTCATTATAAAAG | TTGGGCTTAGGGCAG | 45 | 920 | [ |
| VEB-1 | ATGAAAATCGTAAAAAGGATATT | TTATTTATTCAAATAGTAATTCC | 48 | 900 | |
| CTX − M | ATGATGACTCAGAGCATTCGCCGCT | TCAGAAACCGTGGGTTACGATTTTCG | 70 | 876 | |
| TEM | AAACGCTGGTGAAAGTA | AGCGATCTGTCTAT | 45 | 752 | |
| SHV | ATGCGTTATATTCGCCTGTG | TGCTTTGTTATTCGGGCCAA | 60 | 753 | |
| VIM | TTTGGTCGCATATCGCAACG | CCATTCAGCCAGATCGGCAT | 66 | 500 | |
| GIM | TCAATTAGCTCTTGGGCTGAC | CGGAACGACCATTTGAATGG | 53 | 729 | |
| IMP | GTTTATGTTCATACWTCG | GGTTTAAYAAAACAACCAC | 45 | 188 | |
| SIM | TACAAGGGATTCGGCATCG | TAATGGCCTGTTCCCATGTG | 58 | 741 | [ |
| NDM − 1 | GGTTTGGCGATCTGGTTTTC | CGGAATGGCTCATCACGATC | 52 | 621 | [ |
| GTAATTCTGAGCACTGTCGC | CTGCCTGGACAACATTGCTT | 62 | 954 | ||
| CTCAGTATTCCAAGCCTTTG | ACTCCCCTGAGCTTGAGGGG | 57 | 414 | ||
| CAGTGGACATAAGCCTGTTC | CCCGAGGCATAGGCTGTA | 55 | 160 | [ | |
| TTG CGA GTA TCC ATA ACC TG | TTA CCT GCA CTG GAT TAA GC | 55 | 288 | ||
| GCCTCCGGCAGCGACTTTCAG | ACGGATCTGCCAAACCTGACT | 62 | 980 | [ |
Fig. 1The relative geographical location of each hospital centers are marked in different colors, and the numbers of isolates and constituent ratios are added to the side of the map
Distribution of isolates according to demographic characterization
| Parameters | Sample proportion (N/%) |
|---|---|
| Mean age ± SD | 29.74 ± 23 |
| Age groups (y) | |
| 0–10 | 33 (20.2) |
| 11–20 | 22 (13.5) |
| 21–30 | 27 (16.6) |
| 31–40 | 31 (19) |
| 41–50 | 21 (12.9) |
| > 50 | 29 (17.8) |
| Gender (male/female) | |
| Male | 89 (54.6) |
| Female | 74 (45.4) |
Results of antibiotics resistance profile by disk diffusion among A. baumannii isolates
| Test Group | Antimicrobial agents | |||
|---|---|---|---|---|
| S | I | R | ||
| Penicillins | Piperacillin | 6 (3.7) | 2 (1.3) | 155 (95.1) |
| β-lactam/ β-lactamase inhibitor combinations | Ampicillin-sulbactam | 32 (19.6) | 7 (4.3) | 124 (76.1) |
| Piperacillin-Tazobactam | 11 (6.7) | 5 (3.1) | 147 (90.2) | |
| Cephems | Ceftazidime | 3 (1.8) | 1 (0.6) | 159 (97.5) |
| Cefepime | 2 (1.3) | 8 (4.9) | 153 (93.8) | |
| Cefotaxime | 0 (0) | 1 (0.6) | 162 (99.4) | |
| Ceftriaxone | 0 (0) | 0 (0) | 163 (100) | |
| Aminoglycosides | Amikacin | 13 (7.9) | 8 (4.9) | 142 (87.2) |
| Gentamicin | 10 (6.2) | 3 (1.8) | 150 (92.1) | |
| Tobramycin | 12 (7.4) | 2 (1.2) | 149 (91.4) | |
| Fluoroquinolones | Ciprofloxacin | 4 (2.5) | 2 (1.2) | 157 (96.3) |
| Levofloxacin | 8 (4.9) | 0 (0) | 155 (95.1) | |
| Gatifloxacin | 18 (11.1) | 0 (0) | 145 (89) | |
| Folate Pathway Inhibitors | Co-Trimoxazole | 2 (1.2) | 0 (0) | 161 (98.8) |
| Ansamycins | Rifampin | 10 (6.2) | 0 (0) | 153 (93.8) |
Minimum inhibitory concentration (MIC) of seven antimicrobial agents against A. baumannii isolates
| Antimicrobial agent | MIC (mg/L) | Percent of isolates (%) | Total | ||||
|---|---|---|---|---|---|---|---|
| Range | 50% | 90% | S | I | R | ||
| Imipenem | 2–256 | 32 | 256 | 9 (5.5) | 0 (0) | 154 (94.5) | 163 |
| Meropenem | 2–256 | 32 | 128 | 9 (5.5) | 0 (0) | 154 (94.5) | |
| Colistin | < 0.25–8 | 2 | 4 | 140 (85.9) | 0 (0) | 23 (14.1) | |
| Polymyxin B | < 0.25–8 | 1 | 2 | 163 (100) | 0 (0) | 0 (0) | |
| Doxycycline | 2–256 | 32 | 64 | 17 (10.4) | 10 (6.2) | 136 (83.4) | |
| Minocycline | 2–256 | 4 | 16 | 57 (34.97) | 22 (13.49) | 84 (51.53) | |
| Tetracycline | 2–256 | 32 | 128 | 11 (6.7) | 6 (3.7) | 146 (89.6) | |
Abbreviations: I intermediate, R resistant, S susceptible
The association between the minimum inhibitory concentrations and blaOXA carbapenemase genes of 154 isolates that were resistant to imipenem and meropenem
| Target genes | Number of isolates with minimal inhibitory concentration of imipenema and meropenemb | No. (%) of isolate | ||||||
|---|---|---|---|---|---|---|---|---|
| 8 μg/ml | 16 μg/ml | 32 μg/ml | 64 μg/ml | 128 μg/ml | 256 μg/ml | |||
| 2 (1.5) | 28 (21.4) | 41 (31.3) | 32 (24.4) | 15 (11.5) | 13 (9.9) | 0.1 | 131 (85.1) | |
| 4 (4.8) | 9 (10.7) | 13 (15.5) | 29 (34.5) | 19 (22.6) | 10 (11.9) | 0.2 | 84 (54.5) | |
| 10 (6.5) | 32 (20.8) | 42 (27.3) | 35 (22.7) | 22 (14.3) | 13 (8.5) | 0.1 | 154 (100) | |
| 2 (2.8) | 7 (10) | 13 (18.6) | 26 (37.2) | 13 (18.6) | 9 (12.8) | 0.1 | 70 (45.5) | |
| IS | 0 (0) | 28 (21.7) | 41 (31.8) | 32 (24.8) | 15 (11.6) | 13 (10.1) | 0.1 | 129 (83.8) |
| IS | 0 (0) | 2 (4.8) | 7 (16.7) | 8 (19.1) | 12 (28.6) | 13 (30.9) | 0.2 | 42 (27.3) |
| 1 (0.8) | 31 (23.7) | 33 (25.2) | 29 (22.1) | 22 (16.8) | 15 (11.4) | 0.08 | 131 (85.1) | |
| 2 (2.4) | 6 (7.2) | 15 (17.8) | 30 (35.7) | 21 (25) | 10 (11.9) | 0.09 | 84 (54.5) | |
| 3 (1.9) | 42 (27.3) | 34 (22.1) | 30 (19.5) | 29 (18.8) | 16 (10.4) | 0.2 | 154 (100) | |
| 1 (1.4) | 3 (4.3) | 11 (15.7) | 27 (38.6) | 20 (28.6) | 8 (11.4) | 0.1 | 70 (45.5) | |
| IS | 0 (0) | 30 (23.2) | 33 (25.6) | 29 (22.5) | 22 (17.1) | 15 (11.6) | 0.08 | 129 (83.8) |
| IS | 0 (0) | 3 (7.2) | 5 (11.9) | 13 (30.9) | 10 (23.8) | 11 (26.2) | 0.2 | 42 (27.3) |
Abbreviations: arelated to the concentration of imipenem; brelated to the concentration of meropenem
MBL and ESBL genes detected in A. baumannii isolates
| Phenotypes and related Genes | Regional profile | Total (%) | ||
|---|---|---|---|---|
| Arak (%) | Kermanshah (%) | Ahvaz (%) | ||
| MBLs | 47 (31.9) | 32 (21.8) | 68 (46.3) | 147 (100) |
| 33 (37.1) | 17 (19.1) | 39 (43.8) | 89 (100) | |
| 21 (45.7) | 7 (15.2) | 18 (39.1) | 46 (100) | |
| ESBLs | 25 (29.4) | 19 (22.4) | 41 (48.2) | 85 (100) |
| 14 (29.8) | 12 (25.6) | 20 (42.6) | 47 (100) | |
| 푏푙푎VEB-1 | 11 (30.6) | 0 (0) | 25 (69.4) | 36 (100) |
| 5 (17.8) | 9 (32.2) | 14 (50) | 28 (100) | |
| 0 (0) | 8 (72.7) | 3 (27.3) | 11 (100) | |
| 0 (0) | 0 (0) | 23 (100) | 23 (100) | |
| 24 (24.2) | 27 (27.3) | 48 (48.5) | 99 (100) | |
Fig. 2The 41 representative clusters identified by Pulsed-field gel electrophoresis in Acinetobacter baumannii isolates using the UPGMA based on Dice similarity